Functional Annotation of a Full-Length Mouse Cdna Collection
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Heterogeneity of Usher Syndrome Type II
J7Med Genet 1996;33:753-757 753 Genetic heterogeneity of Usher syndrome type II in a Dutch population J Med Genet: first published as 10.1136/jmg.33.9.753 on 1 September 1996. Downloaded from S Pieke-Dahl, A van Aarem, A Dobin, C W R J Cremers, W J Kimberling Abstract In 1959, Hallgren' laid the foundation for the The Usher syndromes are a group ofauto- clinical definition of US in a study of 172 US somal recessive disorders characterised patients from Sweden. Hallgren' showed sig- by retinitis pigmentosa (RP) with con- nificant phenotypic heterogeneity of US by genital, stable (non-progressive) sen- describing two clinically distinct forms, Usher sorineural hearing loss. Profound deaf- syndrome type I and Usher syndrome type II. ness, RP, and no vestibular responses are Profound congenital deafness, RP, and absent features of Usher type I, whereas moder- vestibular responses was defined as Usher I, ate to severe hearing loss and RP with while those exhibiting a congenital moderate to normal vestibular function describe severe hearing loss, RP, and no associated ves- Usher type II. The gene responsible for tibular problems was defined as Usher II.2 3 most cases ofUsher II, USH2a, is on chro- Although the existence of a type of US with mosome 1q41; at least one other Usher II progressive hearing loss had been proposed,4 gene (as yet unlinked) is known to exist. there was no firm genetic evidence for a Usher III presents with a progressive separate Usher III phenotype until a group of hearing loss that can mimic the audiomet- Finnish families with a phenotype of progres- ric profile seen in Usher II. -
The USH2A C.2299Delg Mutation: Dating Its Common Origin in a Southern European Population
European Journal of Human Genetics (2010) 18, 788–793 & 2010 Macmillan Publishers Limited All rights reserved 1018-4813/10 www.nature.com/ejhg ARTICLE The USH2A c.2299delG mutation: dating its common origin in a Southern European population Elena Aller1,2, Lise Larrieu3, Teresa Jaijo1,2, David Baux3, Carmen Espino´s2, Fernando Gonza´lez-Candelas4,5,6, Carmen Na´jera7, Francesc Palau2,8, Mireille Claustres3,9,10, Anne-Franc¸oise Roux3,9 and Jose´ M Milla´n*,1,2 Usher syndrome type II is the most common form of Usher syndrome. USH2A is the main responsible gene of the three known to be disease causing. It encodes two isoforms of the protein usherin. This protein is part of an interactome that has an essential role in the development and function of inner ear hair cells and photoreceptors. The gene contains 72 exons spanning over a region of 800 kb. Although numerous mutations have been described, the c.2299delG mutation is the most prevalent in several populations. Its ancestral origin was previously suggested after the identification of a common core haplotype restricted to 250 kb in the 5¢ region that encodes the short usherin isoform. By extending the haplotype analysis over the 800 kb region of the USH2A gene with a total of 14 intragenic single nucleotide polymorphisms, we have been able to define 10 different c.2299delG haplotypes, showing high variability but preserving the previously described core haplotype. An exhaustive c.2299delG/control haplotype study suggests that the major source of variability in the USH2A gene is recombination. Furthermore, we have evidenced twice the amount of recombination hotspots located in the 500 kb region that covers the 3¢ end of the gene, explaining the higher variability observed in this region when compared with the 250 kb of the 5¢ region. -
Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma
Anatomy and Pathology Whole-Genome Microarray Detects Deletions and Loss of Heterozygosity of Chromosome 3 Occurring Exclusively in Metastasizing Uveal Melanoma Sarah L. Lake,1 Sarah E. Coupland,1 Azzam F. G. Taktak,2 and Bertil E. Damato3 PURPOSE. To detect deletions and loss of heterozygosity of disease is fatal in 92% of patients within 2 years of diagnosis. chromosome 3 in a rare subset of fatal, disomy 3 uveal mela- Clinical and histopathologic risk factors for UM metastasis noma (UM), undetectable by fluorescence in situ hybridization include large basal tumor diameter (LBD), ciliary body involve- (FISH). ment, epithelioid cytomorphology, extracellular matrix peri- ϩ ETHODS odic acid-Schiff-positive (PAS ) loops, and high mitotic M . Multiplex ligation-dependent probe amplification 3,4 5 (MLPA) with the P027 UM assay was performed on formalin- count. Prescher et al. showed that a nonrandom genetic fixed, paraffin-embedded (FFPE) whole tumor sections from 19 change, monosomy 3, correlates strongly with metastatic death, and the correlation has since been confirmed by several disomy 3 metastasizing UMs. Whole-genome microarray analy- 3,6–10 ses using a single-nucleotide polymorphism microarray (aSNP) groups. Consequently, fluorescence in situ hybridization were performed on frozen tissue samples from four fatal dis- (FISH) detection of chromosome 3 using a centromeric probe omy 3 metastasizing UMs and three disomy 3 tumors with Ͼ5 became routine practice for UM prognostication; however, 5% years’ metastasis-free survival. to 20% of disomy 3 UM patients unexpectedly develop metas- tases.11 Attempts have therefore been made to identify the RESULTS. Two metastasizing UMs that had been classified as minimal region(s) of deletion on chromosome 3.12–15 Despite disomy 3 by FISH analysis of a small tumor sample were found these studies, little progress has been made in defining the key on MLPA analysis to show monosomy 3. -
Meta-Analysis of Nasopharyngeal Carcinoma
BMC Genomics BioMed Central Research article Open Access Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation Xia Chen†1,2, Shuang Liang†1, WenLing Zheng1,3, ZhiJun Liao1, Tao Shang1 and WenLi Ma*1 Address: 1Institute of Genetic Engineering, Southern Medical University, Guangzhou, PR China, 2Xiangya Pingkuang associated hospital, Pingxiang, Jiangxi, PR China and 3Southern Genomics Research Center, Guangzhou, Guangdong, PR China Email: Xia Chen - [email protected]; Shuang Liang - [email protected]; WenLing Zheng - [email protected]; ZhiJun Liao - [email protected]; Tao Shang - [email protected]; WenLi Ma* - [email protected] * Corresponding author †Equal contributors Published: 7 July 2008 Received: 16 February 2008 Accepted: 7 July 2008 BMC Genomics 2008, 9:322 doi:10.1186/1471-2164-9-322 This article is available from: http://www.biomedcentral.com/1471-2164/9/322 © 2008 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Epstein-Barr virus (EBV) presumably plays an important role in the pathogenesis of nasopharyngeal carcinoma (NPC), but the molecular mechanism of EBV-dependent neoplastic transformation is not well understood. The combination of bioinformatics with evidences from biological experiments paved a new way to gain more insights into the molecular mechanism of cancer. Results: We profiled gene expression using a meta-analysis approach. Two sets of meta-genes were obtained. Meta-A genes were identified by finding those commonly activated/deactivated upon EBV infection/reactivation. -
Genomic Profiling of Adult Acute Lymphoblastic Leukemia by Single
SUPPLEMENTARY APPENDIX Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia Ryoko Okamoto,1 Seishi Ogawa,2 Daniel Nowak,1 Norihiko Kawamata,1 Tadayuki Akagi,1,3 Motohiro Kato,2 Masashi Sanada,2 Tamara Weiss,4 Claudia Haferlach,4 Martin Dugas,5 Christian Ruckert,5 Torsten Haferlach,4 and H. Phillip Koeffler1,6 1Division of Hematology and Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA; 2Cancer Genomics Project, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 3Department of Stem Cell Biology, Graduate School of Medical Science, Kanazawa University 4MLL Munich Leukemia Laboratory, Munich, Germany; 5Department of Medical Informatics and Biomathematics, University of Münster, Münster, Germany; 6Cancer Science Institute of Singapore, National University of Singapore, Singapore Citation: Okamoto R, Ogawa S, Nowak D, Kawamata N, Akagi T, Kato M, Sanada M, Weiss T, Haferlach C, Dugas M, Ruckert C, Haferlach T, and Koeffler HP. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonu- cleotide microarray and comparison to pediatric acute lymphoblastic leukemia. Haematologica 2010;95(9):1481-1488. doi:10.3324/haematol.2009.011114 Online Supplementary Data ed by PCR of genomic DNA and subsequent direct sequencing of SNP in a region of CNN-LOH in an ALL sample versus the corresponding Design and Methods matched normal sample (Online Supplementary -
The DEK Oncoprotein and Its Emerging Roles in Gene Regulation
Leukemia (2015) 29, 1632–1636 © 2015 Macmillan Publishers Limited All rights reserved 0887-6924/15 www.nature.com/leu CONCISE REVIEW The DEK oncoprotein and its emerging roles in gene regulation C Sandén and U Gullberg The DEK oncogene is highly expressed in cells from most human tissues and overexpressed in a large and growing number of cancers. It also fuses with the NUP214 gene to form the DEK-NUP214 fusion gene in a subset of acute myeloid leukemia. Originally characterized as a member of this translocation, DEK has since been implicated in epigenetic and transcriptional regulation, but its role in these processes is still elusive and intriguingly complex. Similarly multifaceted is its contribution to cellular transformation, affecting multiple cellular processes such as self-renewal, proliferation, differentiation, senescence and apoptosis. Recently, the roles of the DEK and DEK-NUP214 proteins have been elucidated by global analysis of DNA binding and gene expression, as well as multiple functional studies. This review outlines recent advances in the understanding of the basic functions of the DEK protein and its role in leukemogenesis. Leukemia (2015) 29, 1632–1636; doi:10.1038/leu.2015.72 INTRODUCTION DNA-binding structure in the C-terminal end of the protein 18 The DEK gene was originally discovered as a fusion partner in the (Figure 1). The specificity of the binding between DEK and DNA (6;9)(p23;q34) chromosomal translocation in acute myeloid has been investigated in several studies, demonstrating that it leukemia (AML), described in detail below.1 Since then, DEK has depends on either the sequence or the structure of the chromatin been shown to be expressed in most human cells and tissues and and that it correlates with the transcriptional activity of the gene. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Mutation Screening of the USH2A Gene in Retinitis Pigmentosa and USHER Patients in a Han Chinese Population
Eye (2018) 32:1608–1614 https://doi.org/10.1038/s41433-018-0130-3 ARTICLE Mutation screening of the USH2A gene in retinitis pigmentosa and USHER patients in a Han Chinese population 1,2,3 1 1 1 4 1,2,3 Lulin Huang ● Yao Mao ● Jiyun Yang ● Yuanfeng Li ● Yang Li ● Zhenglin Yang Received: 12 October 2016 / Revised: 1 January 2018 / Accepted: 25 April 2018 / Published online: 13 June 2018 © The Author(s) 2018. This article is published with open access Abstract Objectives USH2A encodes for usherin, a basement membrane protein in the inner ear and retina. USH2A can cause retinitis pigmentosa (RP) with or without hearing loss. The aim of this study was to detect USH2A mutations in a Chinese cohort of 75 small RP families and 10 Usher syndrome families. Methods We performed a direct Sanger sequencing analysis of the USH2A gene to identify mutations for this cohort. Results We identified a total of eight mutations in four of the 75 small RP families (5.3%) and two mutations in one of the 10 Usher families (10%); all families were detected to have compound heterozygous mutations. In families with non- syndromic RP, we identified the compound heterozygous mutations p.Pro4818Leuand p.Leu2395Hisfs*19 in family No. 1234567890();,: 1234567890();,: 19114, p.Arg4493His and p.His1677Glnfs*15 in family No.19162, c.8559-2A > G and p.Arg1549* in family No.19123 and p.Ser5060Pro and p.Arg34Leufs*41 in family No.19178. We also identified the heterozygous mutations p.Arg3719His and p.Cys934Trp in family No.19124, which was the Usher syndrome family. -
Real-Time PCR Analysis of Af4 and Dek Genes Expression in Acute Promyelocytic Leukemia T (15; 17) Patients
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 36, No. 3, 279-282, June 2004 Real-Time PCR analysis of af4 and dek genes expression in acute promyelocytic leukemia t (15; 17) patients Hakan Savli1, Sema Sirma2, Keywords: af4; APL; dek; Gene expression; Real Time Balint Nagy3, Melih Aktan4, PCR Guncag Dincol4, Zafer Salcioglu5, 4 2,6 Nazan Sarper and Ugur Ozbek Introduction 1 Department of Medical Biology Translocation associated gene fusions are well known Medical Faculty, University of Kocaeli, Kocaeli, Turkey, incidents in acute myeloid leukemia while the other 2Departments of Genetics genetic changes are less known. Acute promyelocytic Institute for Experimental Medicine (DETAE) leukaemia (APL) which is characterized by a recip- Istanbul University, Istanbul, Turkey rocal t (15; 17) translocation of fusing the pml gene 31st Department of Obstetrics and Gynecology to the retinoic acid receptor alpha (rar-alpha) gene, Semmelweis University, Budapest, Hungary but probably there are more oncogenes responsible 4Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey in APL pathogenesis. Among several newly identified 5SSK Bakirkoy Hospital, Istanbul, Turkey oncogenes, dek and af4 are attractive targets for 6Corresponding author: Tel, 90-533-4275272; researchers interested with leukemia. Single role of Fax, 90-212-6311351; E-mail, [email protected] translocation partners dek and af4 genes in leuke- mogenesis have been shown in previous studies Accepted 12 May 2004 (Domer et al., 1993; Larramendy et al., 2002). We also found that dek and af4 genes were down Abbreviations: APL, acute promyelocytic leukaemia regulated during vitamin D dependent differentiation of acute promyelocytic leukaemia cell line HL-60 cells, in our previous studies, using cDNA array technology (Savli et al., 2002). -
Mouse Mutants As Models for Congenital Retinal Disorders
Experimental Eye Research 81 (2005) 503–512 www.elsevier.com/locate/yexer Review Mouse mutants as models for congenital retinal disorders Claudia Dalke*, Jochen Graw GSF-National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany Received 1 February 2005; accepted in revised form 1 June 2005 Available online 18 July 2005 Abstract Animal models provide a valuable tool for investigating the genetic basis and the pathophysiology of human diseases, and to evaluate therapeutic treatments. To study congenital retinal disorders, mouse mutants have become the most important model organism. Here we review some mouse models, which are related to hereditary disorders (mostly congenital) including retinitis pigmentosa, Leber’s congenital amaurosis, macular disorders and optic atrophy. q 2005 Elsevier Ltd. All rights reserved. Keywords: animal model; retina; mouse; gene mutation; retinal degeneration 1. Introduction Although mouse models are a good tool to investigate retinal disorders, one should keep in mind that the mouse Mice suffering from hereditary eye defects (and in retina is somehow different from a human retina, particular from retinal degenerations) have been collected particularly with respect to the number and distribution of since decades (Keeler, 1924). They allow the study of the photoreceptor cells. The mouse as a nocturnal animal molecular and histological development of retinal degener- has a retina dominated by rods; in contrast, cones are small ations and to characterize the genetic basis underlying in size and represent only 3–5% of the photoreceptors. Mice retinal dysfunction and degeneration. The recent progress of do not form cone-rich areas like the human fovea. -
The Oncoprotein DEK Affects the Outcome of PARP1/2 Inhibition
bioRxiv preprint doi: https://doi.org/10.1101/555003; this version posted February 19, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 1 The oncoprotein DEK affects the outcome of 2 PARP1/2 inhibition during replication stress 3 Magdalena Ganz1¶, Christopher Vogel1¶, Christina Czada1, Vera Jörke1, Rebecca 4 Kleiner1, Agnieszka Pierzynska-Mach2,3, Francesca Cella Zanacchi2,4, Alberto 5 Diaspro2,5, Ferdinand Kappes6, Alexander Bürkle7, and Elisa Ferrando-May1* 6 1Department of Biology, Bioimaging Center, University of Konstanz, Konstanz, 7 Germany 8 2Nanoscopy and NIC@IIT, Istituto Italiano di Tecnologia, Genoa, Italy 9 3Department of Experimental Oncology, European Institute of Oncology, Milan, Italy 10 4Biophysics Institute (IBF), National Research Council (CNR), Genoa, Italy 11 5DIFILAB, Department of Physics, University of Genoa, Genoa, Italy 12 6Xi’an Jiaotong-Liverpool University, Dushu Lake Higher Education Town, Suzhou, 13 China 14 7Department of Biology, Molecular Toxicology Group, University of Konstanz, 15 Konstanz, Germany 16 17 Short title: DEK and PARP in replication stress 18 19 * Corresponding author 20 email: [email protected] 21 22 ¶These authors contributed equally to this work bioRxiv preprint doi: https://doi.org/10.1101/555003; this version posted February 19, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. -
The USH2A Gene: an Analysis of Ultrasonic Vocalizations in a Mouse Model of Usher Syndrome Type 2
University of Connecticut OpenCommons@UConn Honors Scholar Theses Honors Scholar Program Spring 5-1-2018 The USH2A Gene: An Analysis of Ultrasonic Vocalizations in a Mouse Model of Usher Syndrome Type 2 Kiana R. Akhundzadeh [email protected] Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses Part of the Behavioral Neurobiology Commons, Biological Psychology Commons, Cognitive Neuroscience Commons, Cognitive Psychology Commons, Developmental Neuroscience Commons, Developmental Psychology Commons, Genetics Commons, Health Psychology Commons, Laboratory and Basic Science Research Commons, Other Neuroscience and Neurobiology Commons, Public Health Education and Promotion Commons, and the Speech and Hearing Science Commons Recommended Citation Akhundzadeh, Kiana R., "The USH2A Gene: An Analysis of Ultrasonic Vocalizations in a Mouse Model of Usher Syndrome Type 2" (2018). Honors Scholar Theses. 637. https://opencommons.uconn.edu/srhonors_theses/637 The USH2A Gene: An Analysis of Ultrasonic Vocalizations in a Mouse Model of Usher Syndrome Type 2 An Honors Thesis By Kiana Akhundzadeh Thesis Supervisor: R. Holly Fitch Graduate Student: Peter Perrino Akhundzadeh 2 Introduction Usher syndrome (USH) is a complex, rare autosomal recessive genetic disorder that is presented in humans and manifests in its most common form as inherited deaf-blindness [1]. The genetic disorder is characterized by variable degrees of sensorineural hearing loss (SNHL), retinitis pigmentosa (RP), and in some cases, vestibular dysfunction [2]. Usher syndrome has a prevalence of about 1 in 10,000, indicating that it is the most common form of combined deaf-blindness that plagues the human population [1]. The syndrome presents as three clinical types (Usher syndromes type 1, 2 or 3).